Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Purchased by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. grew its holdings in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) by 71.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,000 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Johnson Investment Counsel Inc.’s holdings in Cassava Sciences were worth $28,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Tidal Investments LLC acquired a new position in shares of Cassava Sciences in the third quarter valued at approximately $11,036,000. Raymond James Financial Inc. purchased a new position in Cassava Sciences in the 4th quarter valued at approximately $147,000. Geode Capital Management LLC grew its stake in shares of Cassava Sciences by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,008,593 shares of the company’s stock worth $29,688,000 after acquiring an additional 41,289 shares in the last quarter. Apollon Wealth Management LLC purchased a new stake in shares of Cassava Sciences during the fourth quarter worth $73,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Cassava Sciences in the third quarter valued at $605,000. 38.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of Cassava Sciences in a research note on Tuesday, March 4th.

Cassava Sciences Stock Up 6.9 %

Shares of Cassava Sciences stock opened at $2.79 on Friday. Cassava Sciences, Inc. has a 52-week low of $2.23 and a 52-week high of $42.20. The company has a 50 day moving average of $2.57 and a 200 day moving average of $13.80. The company has a market capitalization of $134.78 million, a P/E ratio of -2.02 and a beta of -1.24.

Cassava Sciences (NASDAQ:SAVA) last issued its earnings results on Monday, March 3rd. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.11. As a group, research analysts anticipate that Cassava Sciences, Inc. will post -3.97 earnings per share for the current fiscal year.

Cassava Sciences Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.